Current Cardiology Reports

, Volume 8, Issue 4, pp 267–271

Clopidogrel treatment surrounding percutaneous coronary intervention: When should it be started and stopped?

Article

Abstract

Clopidogrel pretreatment before percutaneous coronary intervention (PCI) has been shown to decrease major adverse cardiovascular events (MACE) at 1 month. This benefit has been demonstrated in patients spanning the entire spectrum of coronary artery disease. Subsequent dual antiplatelet therapy with aspirin and clopidogrel after stent placement is necessary for the prevention of stent thrombosis. The duration of clopidogrel therapy after stent placement is dependent upon the type of stent placed, and is recommended for a minimum of 4 weeks after bare-metal stent placement, 3 months after sirolimus-eluting stent placement, and 6 months after paclitaxel-eluting stent placement. A longer course of therapy with clopidogrel (12 months) has been recommended by the most recent American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions guidelines for PCI based upon incremental reduction in cardiovascular complications (primarily myocardial infarction). This article reviews the data presently available regarding pretreatment with clopidogrel before PCI, and the strength of evidence supporting long-term dual antiplatelet therapy.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Baim DS, Carrozza JP Jr.: Stent thrombosis. Closing in on the best preventive treatment. Circulation 1997, 95:1098–1100.PubMedGoogle Scholar
  2. 2.
    Serruys PW, Strauss BH, Beatt KJ, et al.: Angiographic follow-up after placement of a self-expanding coronaryartery stent. N Engl J Med 1991, 324:13–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Schatz RA, Baim DS, Leon M, et al.: Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991, 83:148–161.PubMedGoogle Scholar
  4. 4.
    Fischman DL, Leon MB, Baim DS, et al.: A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994, 331:496–501.PubMedCrossRefGoogle Scholar
  5. 5.
    Serruys PW, de Jaegere P, Kiemeneij F, et al.: A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994, 331:489–495.PubMedCrossRefGoogle Scholar
  6. 6.
    • Leon MB, Baim DS, Popma JJ, et al.: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998, 339:1665–1671.Established the efficacy and safety of dual antiplatelet therapy versus systemic anticoagulationPubMedCrossRefGoogle Scholar
  7. 7.
    Schomig A, Neumann FJ, Kastrati A, et al.: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084–1089.PubMedCrossRefGoogle Scholar
  8. 8.
    Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al.: ACC/ AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/ AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006, 113:156–175.PubMedCrossRefGoogle Scholar
  9. 9.
    •• Mehta SR, Yusuf S, Peters RJ, et al.: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527–533.Substudy of the CURE trial establishing the efficacy of clopidogrel preload and long-term therapy in reducing cardiovascular events at long-term follow-up in patients undergoing stenting for ACSPubMedCrossRefGoogle Scholar
  10. 10.
    •• Steinhubl SR, Berger PB, Mann JT 3rd, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411–2420.First randomized trial demonstrating reduction in the combined endpoint of death, MI, and stroke in low-risk PCI patients treated with both a clopidogrel load and long-term therapyPubMedCrossRefGoogle Scholar
  11. 11.
    Yusuf S, Zhao F, Mehta SR, et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494–502.PubMedCrossRefGoogle Scholar
  12. 12.
    Gurbel PA, Bliden KP, Hiatt BL, O#x2019;Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908–2913.PubMedCrossRefGoogle Scholar
  13. 13.
    Kastrati, A., et al.: A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004, 350:232–238.PubMedCrossRefGoogle Scholar
  14. 14.
    Kastrati A, Mehilli J, Schuhlen H, et al.: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004, 44:2133–2136.PubMedCrossRefGoogle Scholar
  15. 15.
    Patti G, Colonna G, Pasceri V, et al.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005, 111:2099–2106.PubMedCrossRefGoogle Scholar
  16. 16.
    Kastrati A, Mehilli J, Neumann FJ, et al.: Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 Randomized Trial. JAMA 2006, 295:1581–1582.CrossRefGoogle Scholar
  17. 17.
    Sabatine MS, Cannon CP, Gibson CM, et al.: Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005, 294:1224–1232.PubMedCrossRefGoogle Scholar
  18. 18.
    Moses JW, Leon MB, Popma JJ, et al.: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003, 349:1315–1323.PubMedCrossRefGoogle Scholar
  19. 19.
    Stone GW, Ellis SG, Cox DA, et al.: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004, 350:221–231.PubMedCrossRefGoogle Scholar
  20. 20.
    Jeremias A, Sylvia B, Bridges J, et al.: Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004, 109:1930–1932.PubMedCrossRefGoogle Scholar
  21. 21.
    • Iakovou I, Schmidt T, Bonizzoni E, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126–2130.Analysis of predictors of ST in the DES eraPubMedCrossRefGoogle Scholar
  22. 22.
    • Cutlip DE, Baim DS, Ho KK, et al.: Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001, 103:1967–1971.Landmark study of predictors of ST in the bare-metal stent eraPubMedGoogle Scholar
  23. 23.
    Virmani R, Guagliumi G, Farb A, et al.: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004, 109:701–705.PubMedCrossRefGoogle Scholar
  24. 24.
    Lemos PA, Serruys PW, van Domburg RT, et al.: Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004, 109:190–195.PubMedCrossRefGoogle Scholar
  25. 25.
    Holmes DR Jr, Leon MB, Moses JW, et al.: Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004, 109:634–640.PubMedCrossRefGoogle Scholar
  26. 26.
    Stone GW, Ellis SG, Cox DA, et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TA XUS stent: the TA XUS-IV trial. Circulation 2004, 109:1942–1947.PubMedCrossRefGoogle Scholar
  27. 27.
    Moreno R, Fernandez C, Hernandez R, et al.: Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005, 45:954–959.PubMedCrossRefGoogle Scholar
  28. 28.
    Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL: What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention? a meta-analysis. J Am Coll Cardiol 2005, 45:941–946.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.The Divisions of Cardiovascular Medicine and Clinical Biometrics, Department of MedicineBrigham and Women#x2019;s HospitalBostonUSA

Personalised recommendations